Topera in the news

• "... the potential to change the standard of care in mapping directed AF ablation. Early data in patients with principally persistent AF was very impressive..."

  UBS Investment Research

  Bruce Nudell, UBS

  March 28, 2011

• "Targeted, single procedure ablation at identified AF sources increased the long-term freedom from AF by 70 percent over the existing standard of care."

  Industry Alert Medical Devices & Supplies. HRS Late Breaking Abstracts

  Kristen Stewart, Deutsche Bank

  May 5, 2011

• "the CONFIRM Trial, presented by Dr. Sanjiv Narayan and colleagues, could potentially represent a paradigm shift in our understanding and ablative treatment approach of persistent atrial fibrillation (AF). This study could dramatically impact AF management..."

  Letter from the Editor-in-Chief. The Journal of Innovations in Cardiac Rhythm Management.

  John Day

  June 29, 2011

• "The results are even more impressive for several reasons: (1) 84% of the FIRM patients were monitored by implantable loop monitors, which is a very precise means to accurately detect episodes of AF; (2) this data described two year outcomes, which speaks to the durability of the approach; (3) this data was accomplished with a single procedure and is considerably better than the conventional method. "

  AF still at the heart of annual HRS meeting.

  Medical Devices Daily. Larry Haimovitch

  May 10, 2011

• "an A-Fib diagnostic tool that we believe could ultimately help drive increasing ablation penetration and sustainable double-digit market growth longer term through improved diagnostic capabilities and potentially shorter overall procedure times."

  Medical Devices - Cardiology. HRS Wrap-Up: Lots of New Products but ICD Market Pressures Too.

  Rick Wise (Leerink Swann)

  May 10, 2011.

• "Topera grabs the spotlight......a significant improvement over standard of care ablation strategies. If the results continue to be positive in future studies, Topera will dramatically change the field of AFib."

  Medical Devices & Hospital Supplies: Top takeaways from Heart Rhythm Society (HRS) conference.

  Tao Levy (Collins Stewart)

  May 9, 2011.

• "The market opportunity is huge, physician interest is high, and the clinical and regulatory hurdles are significantly less than any other meaningful emerging medical technology that we can think of outside of Topera's new AF technology."

  Industry Overview.

  Bob Hopkins (Bank of America Merrill Lynch )

  October 6, 2011.

• "If Topera were to be acquired by one of the catheter ablation companies, it could enable that company to become the leading player in the catheter ablation market, rapidly increase the number of catheter ablation procedures performed, and potentially displace the other competitors."

  Medical Devices & Hospital Supplies: Topera's novel AFib targeting technology receives FDA clearance.

  Tao Levy (Collins Stewart)

  October 6, 2011.